Podcast

Alegent Health: Type 2 Diabetes

John Harris, MD, talks about the risks associated with diabetes and the steps patients can take to protect themselves.

In this Alegent Health Podcast, John Harris, MD, talks about the risks associated with diabetes and the steps patients can take to protect themselves and their family members.

Click here to access this third party resource.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Related Content
David Tak Wai Lui I Credit: ResearchGate
December 20th 2024

Study Shows a U-Shaped Association Between HDL-C, Major Adverse Cardiovascular Events

Chelsie Derman
Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management
December 17th 2024

Video: Exploring Bempedoic Acid: Clinical Indications, Efficacy, and Future Directions in Cardiovascular Risk Management

Pam R. Taub, MD, FACC, FASPC Marc P. Bonaca, MD, MPH
Aldosterone Dysregulation Linked to Notable Risk of Hypertension | Image Credit: CMHC
December 14th 2024

Aldosterone Dysregulation Linked to Notable Risk of Hypertension

Connor Iapoce
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Mifepristone Significantly Reduces HbA1c in Treatment Phase of CATALYST | Image Credit: LinkedIn
December 12th 2024

Mifepristone Notably Reduces HbA1c in Treatment Phase of CATALYST Trial

Connor Iapoce
Insulin Resistance Amplifies Risk of Colorectal Cancer Development | Image Credit: ResearchGate
December 12th 2024

Insulin Resistance Amplifies Risk of Colorectal Cancer Development

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.